How Companion Diagnostics Can Support Targeted Drug Launches
Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval
-
By
-
Jane Li
-
September 29, 2026
-
Clinical Scorecard: How Companion Diagnostics Can Support Targeted Drug Launches
At a Glance
| Category | Detail |
|---|
| Condition | Companion Diagnostics |
| Key Mechanisms | Identifies patients likely to benefit from targeted therapies. |
| Target Population | Patients with advanced cancer. |
| Care Setting | Community hospitals and decentralized care settings. |
Key Highlights
- Diagnostic innovation requires evidence of clinical validity and utility.
- Testing gaps persist despite guidelines and reimbursement pathways.
- Turnaround time is critical for influencing treatment decisions.
- Community hospitals face barriers to implementing advanced testing.
- Collaboration between pharmaceutical and diagnostics companies is essential.
Guideline-Based Recommendations
Diagnosis
- Implement comprehensive genomic profiling in routine practice.
Management
- Develop testing strategies that work in real-world settings.
Monitoring & Follow-up
- Track turnaround times as a measure of test performance.
Risks
- Delays in testing can lead to missed treatment opportunities.
Patient & Prescribing Data
Patients receiving targeted therapy for cancer.
Timely testing is crucial for appropriate treatment decisions.
Clinical Best Practices
- Design CDx programs with end-to-end testing pathways in mind.
- Utilize tissue-conserving methods and validated alternatives for testing.
- Ensure systems are straightforward to operate in community settings.
Related Resources & Content
